Animal models of α -synucleinopathy for Parkinson disease drug development
Nature Reviews Neuroscience 18, 515 (2017).
doi:10.1038/nrn.2017.75
Authors: James B. Koprich, Lorraine V. Kalia & Jonathan M. Brotchie
A major challenge in Parkinson disease (PD) will be to turn an emerging and expanding pipeline of novel disease-modifying candidate compounds into therapeutics. Novel targets need in vivo validation, and candidate therapeutics require appropriate preclinical platforms on which to define potential efficacy and target
Source: Nature Reviews Neuroscience - Category: Neuroscience Authors: James B. Koprich Lorraine V. Kalia Jonathan M. Brotchie Tags: Review Source Type: research